Department of Physical Medicine and Rehabilitation, Taipei Veterans General Hospital, Taipei 112, Taiwan.
Department of Physical Medicine and Rehabilitation, Far Eastern Memorial Hospital, New Taipei City 220, Taiwan.
Int J Mol Sci. 2022 May 27;23(11):6047. doi: 10.3390/ijms23116047.
Muscle wasting, known to develop in patients with chronic kidney disease (CKD), is a deleterious consequence of numerous complications associated with deteriorated renal function. Muscle wasting in CKD mainly involves dysregulated muscle protein metabolism and impaired muscle cell regeneration. In this narrative review, we discuss the cardinal role of the insulin-like growth factor 1 and myostatin signaling pathways, which have been extensively investigated using animal and human studies, as well as the emerging concepts in microRNA- and gut microbiota-mediated regulation of muscle mass and myogenesis. To ameliorate muscle loss, therapeutic strategies, including nutritional support, exercise programs, pharmacological interventions, and physical modalities, are being increasingly developed based on advances in understanding its underlying pathophysiology.
肌肉减少症,已知在慢性肾脏病(CKD)患者中发展,是与肾功能恶化相关的许多并发症的有害后果。CKD 中的肌肉减少症主要涉及肌肉蛋白代谢失调和肌肉细胞再生受损。在本叙述性综述中,我们讨论了胰岛素样生长因子 1 和肌肉生长抑制素信号通路的主要作用,这些通路已通过动物和人体研究进行了广泛研究,以及 miRNA 和肠道微生物群介导的肌肉质量和肌发生调节的新出现概念。为了改善肌肉减少症,基于对其潜在病理生理学的理解,正在越来越多地开发治疗策略,包括营养支持、运动方案、药物干预和物理方式。